Improving risk Assessment: Research opportunities in dose response modeling to improve risk assessment

Human and Ecological Risk Assessment

Volumn 8, Issue 6, 2002, Pages 1421-1444

  Zeise, Lauren ^a   Hattis, Dale ^b   Andersen, Mel ^c   Bailer, A John ^d   Bayard, Steve ^e   Chen, Chao ^f   Clewell, Harvey ^g   Conolly, Rory ^h   Crump, Kenny ^g   Dunson, David ⁱ   Finkel, Adam ^e   Haber, Lynne ^j   Jarabek, Annie M ^k   Kodell, Ralph ^l   Krewski, Daniel ^m   Thomas, Duncan ⁿ   Thorslund, Todd ^e   Wassell, James T ^o  

^a CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b CLARK UNIVERSITY   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d MIAMI UNIVERSITY   (United States)

^e Occupational Safety and Health Administration   (United States)

^f U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^g KS Crump Division   (United States)

^h CIIT CENTERS FOR HEALTH RESEARCH   (United States)

ⁱ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^j Toxicology Excellence for Risk Assessment   (United States)

^k U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^l NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

more..

Author keywords

Bayesian analysis; Injury risk; Interindividual variability; Latent variables; Markov Chain Monte Carlo analysis

Indexed keywords

EID: 2342640696     PISSN: 10807039     EISSN: None     Source Type: Journal    
DOI: 10.1080/20028091057448     Document Type: Conference Paper

References (88)

1. Allen BC, Covington TR, and Clewell HJ. 1996. Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111:289-303
2. Andersen ME and Conolly RB. 1998. Mechanistic modeling of rodent liver tumor promotion at low levels of exposure: An example related to dose response relationships for 2,3,7,8-tetrachlorodibenzo-p-dioxin. Human Experimental Toxicol 17, 683-90; discussion 701-4, 708-18
3. Bailer AJ and Dankovic DA. 1997. An introduction to the use of physiologically-based pharmacokinetc models in risk assessment. Stat Methods Medical Res 6:341-58
4. Bailer AJ, Stayner LT, Smith RJ, et al. 1997. Estimating benchmark concentrations and other non-cancer endpoints in epidemiology studies Risk Anal 17:771-80
5. Baird JS, Cohen JT, Graham JD, et al. 1996. Noncancer risk assessment: Probabilistic characterization of population threshold doses. Human Ecol Risk Assess 2(1):79-102
6. Barrett JC. 1993. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100:9-20
7. Bishop JM. 1987. The molecular genetics of cancer. Science 235:305-11
8. Bogdanffy MS and Jarabek AM 1995. Understanding mechanisms of inhaled toxicants: Implications for replacing default factors with chemical-specific data. Toxicol Lett 82/83:919-32
9. Bogdanffy MS, Sarangapani R, Plowchalk DR, et al. 1999. A biologically-based risk assessment for vinyl-acetate induced cancer and noncancer inhalation toxicity. Toxicol Sci 51:19-35
10. Bogen KT. 1998. Mechanistic model predicts a U-shaped relation of radon exposure to lung cancer risk reflected in combined occupational and US residential data. Human Experimental Toxicol 17:691-6
11. Bogen KT and Spear RC. 1987. Integrating uncertainty and interindividual variability in environmental risk assessment. Risk Anal 7:427-36
12. Bois FY. 1999. Analysis of PBPK models for risk characterization. Ann NY Acad Sci 895:317-37
13. Bois FY, Gelman A, Jiang J, et al. 1996. Population toxicokinetics of tetrachloroethylene. Arch Toxicol 70(6):347-55
14. Bois FY, Krowech G, and Zeise L. 1995. Modeling human interindividual variability in metabolism and risk: the example of 4-aminobiphenyl. Risk Anal 15:205-13
15. Bois FY, Zeise L, and Tozer TN. 1990. Precision and sensitivity of pharmacokinetic models for cancer risk assessment: Tetrachloroethylene in mice, rats, and humans. Toxicol Applied Pharmacol 102:300-15
16. Calabrese EJ, Baldwin LA, and Holland CD. 1999. Hormesis: a highly generalizable and reproducible phenomenon with important implications for risk assessment. Risk Anal 19:261-81
17. California Environmental Protection Agency. 2000. Draft Public Health Goal for Tetrachloroethylene in Drinking Water. Office of Environmental Health Hazard Assessment, Sacramento, CA, USA
18. Chemical Industry Institute of Toxicology (CIIT). September 28, 1999. Formaldehyde: Hazard Characterization and Dose Response Assessment for Carcinogenicity by the Route of Inhalation. Revised Edition. Chemical Industry Institute of Toxicology, Research Triangle Park, NC, USA
19. Chien JY, Thummel KE, and Slattery JT. 1997. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 25:1165-75
20. Clewell HJ. 1995. The use of physiologically based pharmacokinetic modeling in risk assessment: A case study with methylene chloride. In: Olin S, Farland W, Park C, et al. (eds), Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives. ILSI Press, Washington, DC, USA
21. Clewell HJ, Gearhart JM, Gentry PR, et al. 1999. Evaluation of the uncertainty in an oral Reference Dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 19:541-52
22. Clewell HJ and Jarnot BM. 1994. Incorporation of pharmacokinetics in non-carcinogenic risk assessment: Example with chloropentafluorobenzene. Risk Anal 14:265-76
23. Clewell HJ, III and Andersen ME. 1996. Use of physiologically-based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315-29
24. Cordon-Cardo C, Dalbagni G, Sarkis AS, et al. 1994. Genetic alterations associated with bladder cancer. Important Advances in Oncology 1994:71-83
25. Crump KS, Hoel DG, Langley CH, et al. 1976. Fundamental carcinogenic processes and their implication for low dose risk assessment. Cancer Res 36:2973-9
26. Crump KS, Krewski D, and VanLandingham C. 1999. Estimates of the proportion of chemicals that were carcinogenic or anticarcinogenic in bioassays conducted by the National Toxicology Program. Environ Health Perspect 107:83-8
27. Cullen AC and Frey HC. 1999. Probabilistic Techniques in Exposure Assessment - A Handblook for Dealing with Variability and Uncertainty in Models and Inputs. Plenum Press, NY, NY, USA
28. Dankovic D and Bailer AJ. 1994. The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically-based pharmacokinetic model. Fund Applied Toxicol 22:20-5
29. Dietert RR, Etzel RA, Chen D, et al. 2000. Workshop to identify critical windows of exposure to children's health: Immune and respiratory systems work group summary. Environ Health Perspect 108(suppl. 3):483-90
30. Dourson M, Maier A, Meek B, et al. 1998. Boron tolerable intake: Re-evaluation of toxicokinetics for data-derived uncertainty factors. Biol Trace Elem Res 66:453-63
31. Dunson DB. 2000. Bayesian latent variable models for clustered mixed outcomes. J R Stat Soc B 62 (part 2):355-66
32. Fearon ER and Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-67
33. Finkel AM. 1987. Uncertainty, Variability and the Value of Information in Cancer Risk Assessmentt. Ph.D. Dissertation. Harvard University, Harvard School of Public Health, Cambridge, MA, USA
34. Finkel AM. 1995. A quantitative estimate of the variations in human susceptibility to cancer and its implications for risk management. In: Olin S, et al. (eds), Low-Dose Extrapolation of Cancer Risks: Issues and Perspectives, pp 297-328. ILSI Press, Washington, DC, USA
35. Fosbroke DE, Kisner SM, and Myers JR. 1997. Working lifetime risk of occupational fatal injury. Am J Ind Med 31:459-67
36. Gilbert SJ, Bailer AJ, Stayner LT. 1998. Years of Potential Life Lost due to Occupational Fatal Injury in the United States. Human Ecol Risk Assess 4(6):1321-35
37. Grossman D and Leffell DJ. 1997. The molecular basis of nonmelanoma skin cancer: new understanding. Archives Dermatol 133(10):1263-70
38. Hasselblad V and Jarabek AM. 1996. Dose-response analysis of toxic chemicals. In: Berry DA and Stangle DK (eds), Bayesian Biostatistics. Marcel Dekker, Inc., NY, NY, USA
39. Hattis D. 1996. Human interindividual variability in susceptibility to toxic effects - from annoying detail to a central determinant of risk. Toxicology 111:5-14
40. Hattis D. 1997. Invited comment on Heitzman, M., and Wilson, R. low dose linearity: The rule or the exception. Belle Newsletter 6:21-4
41. Hattis D. 1998. Strategies for assessing human variability in susceptibility, and variability to infer human risks. In: Neumann DA and Kimmel CA (eds) Human Variability in Response to Chemical Exposure: Measures, Modeling, and Risk Assessment, pp 27-57. CRC Press, Boca Raton, FL, USA
42. Hattis D and Anderson E. 1999. What should be the implications of uncertainty, variability, and inherent 'biases'/'conservatism' for risk management decision making? Risk Anal 19:95-107
43. Hattis D, Banati P, Goble R, et al. 1999. Human interindividual variability in parameters related to health risks. Risk Anal 19:705-20
44. Hattis D and Barlow K. 1996. Human Interindividual Variability in Cancer Risks - Technical And Management Challenge. Health Ecol Risk Assess 2:194-220
45. Hattis D and Burmaster DE. 1994. Assessment of variability and uncertainty distributions for practical risk analyses. Risk Anal 14:713-30
46. Hattis D and Minkowitz WS. 1996. Risk evaluation: criteria arising from legal traditions and experience with quantitative risk assessment in the United States. Environmental Toxicol Pharmacol 2:103-9
47. Hattis D and Silver K. 1994. Human interindividual variability - a major source of uncertainty in assessing risks for non-cancer health effects. Risk Anal 14:421-31
48. Integrated Risk Information System (IRIS). October 1999. Toxicological review of ethylene glycol monobutyl ether (EGBE) CAS no. 111-76-2. National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC, USA
49. Integrated Risk Information System (IRIS). May 2000. Toxicological review of vinyl chloride CAS no. 75-01-4. National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC, USA
50. Internation Programme for Chemical Safety (IPCS). 1998. Boron. Environmental Health Criteria. 204. World Health Organization, Geneva, Switzerland
51. Jarabek AM. 1995a. Interspecies extrapolation based on mechanistic determinants of chemical disposition. Human Ecol Risk Assess 1(5):641-62
52. Jarabek AM. 1995b. The application of dosimetry models to identify key processes and parameters for default dose response assessment approaches. Toxicol Lett 79:171-84
53. Jarabek AM. 1999. Application requirements for biomarkers in risk assessment. Presented at Biomarkers: Taking stock - An EPA/NIEHS In-house Workshop on applying biomarker research, 30-31 August 1999, Research Triangle Park, NC, USA (Manuscript in preparation)
54. Jarabek AM. 2000. Mode of Action: Framework for dosimetry model development. Presented in: Mode-of-Action Dosimetry: An interagency project to develop models for inhalation, oral and dermal disposition. Annual meeting of the Society for Risk Analysis, 4-6 December, Arlington, VA, USA (Manuscript in preparation)
55. Jonsson F and Johanson G. 2000. Improving the reliability of parameters in PBTK models using Markov Chain Monte Carlo simulation. (Abstract No. 422) Toxicologist 54:90
56. Kohn MC. 1995. Achieving credibility in risk assessment models. Toxicol Letters 79:107-14
57. Kohn MC. 1997. The importance of anatomical realism for validation of physiological models of disposition of inhaled toxicants. Toxicol Appl Pharmacol 147:448-58
58. Krewski D, Rai SN, Zielinski JM, et al. 1999. Characterization of uncertainty and variability in residential radon cancer risks. Annals NY Academy Sciences 895:245-72
59. Leisenring W and Ryan L. 1992. Statistical properties of the NOAEL. Reg Toxicol Pharmacol 15(2):161-71
60. Lutz WK. 1998. Dose response relationships in chemical carcinogenesis: superposition of different mechanisms of action, resulting in linear-nonlinear curves, practical thresholds, J-shapes. Mutation Res 405:117-24
61. Lutz WK and Kopp-Schneider. 1999. Threshold dose response for tumor induction by genotoxic carcinogens modeled via cell-cycle delay. Toxicol Sciences 49:110-5
62. Manton KG and Stallard E. 1979. Maximum likelihood estimation of a stochastic compartment model of cancer latency: lung cancer mortality among white females in the U.S. Computers and Biomedical Res 12:313-25
63. Manton KG, Stallard E, and Vaupel J, 1986. Alternative models for the heterogeneity of mortality risks among the aged. J Am Stat Assoc 81:635-44
64. Mao L, Lee JS, Kurie JM, et al. 1997. Clonal genetic alterations in the lungs of current and former smokers. J National Cancer Institute 89(12):857-62
65. Meek ME, Ohanian E, Renwick A, et al. 2000. Guidelines for application of data-derived uncertainty factors in risk assessment. Submitted.
66. National Research Council. 2000. Acute Exposure Guideline Levels for Selected Airborne Chemicals, Volume 1. National Academy Press, Washington, DC, USA
67. National Research Council. 2001. Standing Operating Procedures for Developing Acute Exposure Guideline Levels for Hazardous Substances. National Academy Press, Washington, DC (in press).
68. Occupational Safety and Health Administration (OSHA). 1997. Occupational exposure to methylene chloride; final rule. Fed Reg 62(7):1493-619
69. Price PS, Keenan RE, Swartout JC, et al. 1997. An approach for modeling noncancer dose responses with an emphasis on uncertainty. Risk Anal 17(4):427-37
70. Renwick AG. 1991. Safety factors and establishment of acceptable daily intakes. Food Add Contam 8(2):135-50
71. Renwick AG and Lazarus NR. 1998. Human variability and noncancer risk assessment - an analysis of the default uncertainty factor. Regul Toxicol Pharmacol 27(1 Pt 1):3-20
72. Schlosser PM and Bogdanffy MS. 1999. Determining modes of action for biologically based risk assessments. Regul Toxicol Pharmacol 30:75-9
73. Schwarz M, Buchmann A, Stinchcombe S, et al. 2000. Ah receptor ligands and tumor promotion: survival of neoplastic cells. Toxicol Letters 112-113:69-77
74. See K and Bailer AJ. 1998. Estimates of lifetime risk of occupational fatal injury from age-specific rates. Human Ecol Risk Assess 4(6):1309-19
75. Sekido Y, Fong KM, and Minna JD. 1998. Progress in understanding the molecular pathogenesis of human lung cancer. Biochimica et Biophysica Acta 1378:F21-59
76. Shi ST, Yang FY, Wang LD, et al. 1999. Role of p53 gene mutations in human esophageal carcinogenesis; results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenensis 20:591-7
77. Slob W and Pieters MN. 1997. A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework. 620110005. Rijksinstituut voor Volksgezondheid en Milieu, National Institute of Public Health and the Environment, The Netherlands
78. Sugimura T. 1992. Multistep carcinogenesis: A 1992 perspective. Science 258:603-8
79. Swartout JC, Price PS, Doruson ML, et al. 1998. A probabilistic framework for the reference dose. Risk Anal 18(3):271-82
80. Tan WY and Chen C. 1998. Stochastic modeling of carcinogenesis: Some new insights. Mathematical Computer Modeling 28(11):49-71
81. Thompson KM. 1999. Developing univariate distributions from data for risk analysis. Human and Ecol Risk Assess 5:755-83
82. USEPA (U.S. Environmental Protection Agency). October 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA-600/8-90-066F. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Research Triangle Park, NC, USA
83. USEPA (U.S. Environmental Protection Agency). 1996a. Air Quality Criteria for Particulate Matter-Volume II. EPA-600/P-95-001bF. National Center for Environmental Assessment, Research Triangle Park, NC. Available from NTIS, Springfield, VA, USA; PB96-168224.
84. USEPA (U.S. Environmental Protection Agency). 1996b. Proposed guidelines for carcinogen risk assessment. Federal Register 61(79):17960-8011
85. USEPA (U.S. Environmental Protection Agency). 2000. Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds. Part II: Health Assessment for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and Related Compounds. Chapter 8. Dose response Modeling for 2,3,7,8-TCDD. NCEA-I-0835, May 2000, SAB Review Draft.
86. Wassell JT. 1998. Probability Models of Occupational Injury. Human Ecol Risk Assess 4(6):1275-83
87. Wienberg RA. 1989. Ocogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-21
88. Williams JR, Russell J, Dicello JF, et al. 1996. The genotype of the human cancer cell: Implications for risk analysis. Mutation Res 365:17-42